Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

DNA Cytosine-Demethylating Agent 5-Aza-2'-Deoxycytidine Targets Leukemia Cells through Reducing DNA N 6 -Methyladenine

Xiaochang Liu, PhD, Jiuxia Pang, Christopher Seiler, Ryan Kempen, Hao Liu, Aref Al-Kali, MD, Y. Natalia Tretyakova, Mark Litzow, MD, Shujun Liu

Blood (2019) 134 (Supplement_1): 2513.

https://doi.org/10.1182/blood-2019-130490

Published: 2019

Journal Articles

AML1/ETO Cooperates with HIF1α to Promote Leukemogenesis through DNMT3a Transactivation

Xiaoning Gao, Fei Yan, PhD, Ji Lin, Li Gao, Xiaolin Lu, Shengcai Wei, Na Shen, Jiuxia Pang, Qiaoyang Ning, Ailing Deng, Yihan Xu, Jinlong Shi, Yonghui Li, Shujun Liu, PhD, Li Yu

Blood (2014) 124 (21): 3543.

https://doi.org/10.1182/blood.V124.21.3543.3543

Published: 2014

Journal Articles

Therapeutic Targeting of the RAS-Pathway by Synthetic Mir-181a Nanoparticles in Acute Myeloid Leukemia (AML).

Blood (2012) 120 (21): 2422.

https://doi.org/10.1182/blood.V120.21.2422.2422

Published: 2012

Journal Articles

Translational Research From the Tropical Forest: Silvestrol, a Natural Product From the Plant Aglaia Foveolata inhibits the Expression of Tyrosine Kinases and Shows a Significant In Vivo Activity in Acute Myeloid Leukemia (AML)

Houda Alachkar, PharmD, M.S, Ramasamy Santhanam, PhD, David M. Lucas, PhD, Sebastian Schwind, MD, Christopher Hickey, M.S, Jiuxia Pang, Danilo Perrotti, MD, PhD, Li Pan, PhD, A Douglas Kinghorn, Ph.D., D.Sc, Guido Marcucci, MD, Michael R Grever, MD

Blood (2011) 118 (21): 2616.

https://doi.org/10.1182/blood.V118.21.2616.2616

Published: 2011

Journal Articles

Targeted Delivery of MicroRNA-29b by Nanoparticles Provides Antileukemic Activity and Increases Sensitivity to the Hypomethylating Agent Decitabine (DAC) in Acute Myeloid Leukemia (AML)

Xiaomeng Huang, Sebastian Schwind, MD, Bo Yu, Ph.D, Jiuxia Pang, Ramasamy Santhanam, Ph.D, Kenneth K. Chan, Ph.D, Ramiro Garzon, MD, William Blum, MD, Clara D. Bloomfield, MD, Shujun Liu, Ph.D, Danilo Perrotti, MD, Ph.D, Robert J. Lee, Ph.D, John C. Byrd, MD, Natarajan Muthusamy, DVM, Ph.D, L. James Lee, Ph.D, Guido Marcucci, MD

Blood (2011) 118 (21): 81.

https://doi.org/10.1182/blood.V118.21.81.81

Published: 2011

Journal Articles

Quantification of Intracellular Decitabine-Triphosphate with A Novel, Highly Sensitive and Specific LC-MS/MS Assay in Acute Myeloid Leukemia Patients Treated with Low Dose Decitabine.

Ping Chen, Ph.D., William Blum, M.D., Josephine Aimiuwu, B.S., Vijayasarathi Upadhyayula, Ph.D., Zhongfa Liu, Ph.D., Shujun Liu, Ph.D., Jiuxia Pang, B.S., Alison Walker, M.D., Rebecca B. Klisovic, M.D., Ramiro Garzon, M.D., Michael R. Grever, M.D., Miguel Villalona-Calero, M.D., John C. Byrd, M.D., Kenneth K Chan, Ph.D., Guido Marcucci, M.D.

Blood (2009) 114 (22): 3782.

https://doi.org/10.1182/blood.V114.22.3782.3782

Published: 2009

Journal Articles

Evidence of MicroRNA-29b and Sp1/NFκB-HDAC Regulatory Network for KIT Expression in KIT-Driven Acute Myeloid Leukemia (AML): Biologic and Therapeutic Implications.

Shujun Liu, PhD, Lai Chu Wu, PhD, Jiuxia Pang, BS, Ramasamy Santhanam, PhD, Sebastian Schwind, MD, Yue-Zhong Wu, MS, Christopher Hickey, MS, Jianhua Yu, PhD, Anjali Mishra, PhD, Heiko Becker, MD, Chenglong Li, PhD, Roger Briesewitz, PhD, Robert A. Baiocchi, MD, Kenneth K. Chan, PhD, Michael A. Caligiuri, MD, John C. Byrd, MD, Danilo Perrotti, MD, PhD, Ramiro Garzon, MD, Guido Marcucci, MD

Blood (2009) 114 (22): 938.

https://doi.org/10.1182/blood.V114.22.938.938

Published: 2009

Journal Articles

MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1

Blood (2009) 113 (25): 6411–6418.

https://doi.org/10.1182/blood-2008-07-170589

Published: 2009

Includes: Supplemental data

Journal Articles

Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-κB–dependent DNA methyltransferase activity in acute myeloid leukemia

Blood (2008) 111 (4): 2364–2373.

https://doi.org/10.1182/blood-2007-08-110171

Published: 2008

Journal Articles

MicroRNA (miRNA)-29b Targets DNMT3A and B and Induces Re-Expression of the Hypermethylated ESR1 and p15 Genes in Acute Myeloid Leukemia (AML).

Ramiro Garzon, Shujun Liu, Muller Fabbri, Zhongfa Liu, Jiuxia Pang, Natarajan Muthusamy, William Blum, Kenneth Chan, John C. Byrd, Carlo M. Croce, Guido Marcucci

Blood (2007) 110 (11): 718.

https://doi.org/10.1182/blood.V110.11.718.718

Published: 2007

Journal Articles

Bortezomib-Induced Down-Regulation of KIT Is Mediated by Inhibition of Sp1 and NF- k B in AML1/ETO-Positive Cells.

Shujun Liu, PhD, Jiuxia Pang, Jianhua Yu, Ph.D., Zhongfa Liu, Ph.D., Lenguyen Huynh, Jessica Kearney, Peter Paschka, M.D., Rebecca B. Klisovic, M.D., Robert Baiocchi, M.D., William Blum, M.D., Danilo Perrotti, Ph.D., Guido Marcucci, M.D.

Blood (2006) 108 (11): 4211.

https://doi.org/10.1182/blood.V108.11.4211.4211

Published: 2006

NARROW

DNA Cytosine-Demethylating Agent 5-Aza-2'-Deoxycytidine Targets Leukemia Cells through Reducing DNA N 6 -Methyladenine

AML1/ETO Cooperates with HIF1α to Promote Leukemogenesis through DNMT3a Transactivation

Therapeutic Targeting of the RAS-Pathway by Synthetic Mir-181a Nanoparticles in Acute Myeloid Leukemia (AML).

Translational Research From the Tropical Forest: Silvestrol, a Natural Product From the Plant Aglaia Foveolata inhibits the Expression of Tyrosine Kinases and Shows a Significant In Vivo Activity in Acute Myeloid Leukemia (AML)

Targeted Delivery of MicroRNA-29b by Nanoparticles Provides Antileukemic Activity and Increases Sensitivity to the Hypomethylating Agent Decitabine (DAC) in Acute Myeloid Leukemia (AML)

Quantification of Intracellular Decitabine-Triphosphate with A Novel, Highly Sensitive and Specific LC-MS/MS Assay in Acute Myeloid Leukemia Patients Treated with Low Dose Decitabine.

Evidence of MicroRNA-29b and Sp1/NFκB-HDAC Regulatory Network for KIT Expression in KIT-Driven Acute Myeloid Leukemia (AML): Biologic and Therapeutic Implications.

MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1

Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-κB–dependent DNA methyltransferase activity in acute myeloid leukemia

MicroRNA (miRNA)-29b Targets DNMT3A and B and Induces Re-Expression of the Hypermethylated ESR1 and p15 Genes in Acute Myeloid Leukemia (AML).

Bortezomib-Induced Down-Regulation of KIT Is Mediated by Inhibition of Sp1 and NF- k B in AML1/ETO-Positive Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only